SAN FRANCISCO--(BUSINESS WIRE)--In 2023, the life sciences industry experienced a 13% year-over-year increase in digital experiences, outpacing the global average by 5 percentage points, according to ...
Pharma company CSL Behring, whose roots go back over a century, has debuted its first-ever TV commercial: a :60 spot for Hizentra, a 15-year-old treatment for the rare disease of primary ...
Narrow-moat CSL reported fiscal 2024 revenue of USD 14.8 billion and net profit after tax before amortization of USD 2.9 billion, up 11% and 15% in constant currency, respectively, close to our ...
Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...
CSL, the Australian biotechnology company behind CSL Behring in King of Prussia, plans to cut up to 15 percent of its global workforce, or about 3,000 jobs worldwide, writes John George for the ...
No articles found. CSL Behring did not contribute to any primary research papers from Nature Index journals in the current 12 month window. The following affiliated institutions are wholly owned, ...
Feb 11 (Reuters) - Australian biopharmaceutical company CSL said on Tuesday that falling immunisation rates in the U.S., its largest market, weighed on its vaccine sales and first-half profit growth, ...
Earnings call CSL reported H1 FY25 revenue of AUD 8.5B (+5% YoY, constant currency) and NPATA of AUD 2.1B (+5%), reaffirming FY25 NPATA guidance of AUD 3.2–3.3B (+10–13%). Behring led with 10% revenue ...
Narrow-moat CSL reiterated fiscal 2025 guidance for constant-currency group net profit after tax before amortization, or NPATA, of USD 3.2 billion to USD 3.3 billion, implying 10%-13% growth on fiscal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results